Related Experiment Videos
Dydrogesterone has no peripheral (anti)-androgenic properties
A J Vermorken1, C Sultan, C M Goos
1INSERM U-58, Biochimie des Stéroïdes, Montpellier, France.
In Vivo (Athens, Greece)
|May 1, 1987
Summary
Dydrogesterone, a progestational drug, was tested for androgenic effects. Studies found no evidence of androgenic or anti-androgenic activity, making it a safe option for gynecologic conditions, even during pregnancy.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Dydrogesterone is an oral progestogen used for various endocrine and gynecologic issues.
- Concerns exist regarding potential hormonal side effects of progestogens.
Purpose of the Study:
- To investigate the peripheral androgenic and anti-androgenic properties of dydrogesterone.
- To assess the safety profile of dydrogesterone concerning androgenic activity.
Main Methods:
- In vivo evaluation using the hamster flank organ test.
- In vitro assays assessing molecular mechanisms of androgen action.
Main Results:
- Dydrogesterone demonstrated no androgenic activity in vivo.
- Dydrogesterone showed no anti-androgenic activity in vitro.
- The compound exhibited neither androgenic nor anti-androgenic properties.
Conclusions:
- Dydrogesterone lacks peripheral androgenic or anti-androgenic effects.
- This finding supports the use of dydrogesterone in conditions where androgenic activity is a concern.
- The absence of androgenic activity is significant given dydrogesterone's use during pregnancy.